VivoSeq
Other

CAR

0

Pipeline Programs↗

45

Active Trials↗

41

Companies Involved↗

CAR is an early-stage landscape with 0 programs across 41 companies. The most active players are Pfizer, Eli Lilly, Sanofi.

Intelligence

Pipeline Metrics

Competitive Density

47/100

Pipeline Velocity

43/100

Mech. Concentration

N/A

Completion Rate

86/100

Attrition Rate

10/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Pfizer logo

Pfizer

0 programs

PreclinicalEli Lilly logo

Eli Lilly

0 programs

PreclinicalSanofi logo

Sanofi

0 programs

PreclinicalGSK logo

GSK

0 programs

PreclinicalBoehringer Ingelheim logo

Boehringer Ingelheim

0 programs

PreclinicalAstraZeneca logo

AstraZeneca

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

322

clinical trials

Completed207 · 64%
Unknown status33 · 10%
Recruiting26 · 8%
Terminated23 · 7%
Withdrawn10 · 3%
Not yet recruiting8 · 2%
Other15 · 5%

Clinical Trials

Trial Activity

322 trials

Beta-blocker Administration for Cardiomyocyte Division
Recruiting·WWeill Medical College of Cornell University·Phase 1·NCT04713657·40 enrolled
Revascularization Effect on CSVD Burden in Carotid Artery Stenosis
Recruiting·ZZhejiang Provincial People's Hospital·N/A·NCT06031610·1,000 enrolled
Cardioprotection in AML
Recruiting·UUniversity of Virginia·Phase 2·NCT04977180·70 enrolled
NAUTICAL: Effect of Natriuretic Peptide Augmentation on Cardiometabolic Health in Black Individuals
Recruiting·UUniversity of Alabama at Birmingham·Phase 2·NCT04055428·200 enrolled
Effect and Safety MABs Administration m.3243A>G Mutation Carriers
Recruiting·MMaastricht University·Phase 2·NCT05962333·20 enrolled
Clinical Investigation of the Cardioprotective Effect of Early Administration of SGLT2 in Patients Presented With AMI
Recruiting·MMohammad Hussien Tantawy Soliman·N/A·NCT06009874·80 enrolled
A Phase I Dose Finding Study of MB-CART2219.1
Recruiting·UUniversity Hospital Tuebingen·Phase 1·NCT07108868·36 enrolled
Hyperemic mYocardial Perfusion by adEnosine at diffeRent Doses
Recruiting·—·Phase 4·NCT06578234·180 enrolled
Comparison of Point-of-care Produced CAR T-cell with Commercial CAR T-cells in Patients with R/R LBCL
Recruiting·UUniversity Medical Center Groningen·Phase 2·NCT05641428·300 enrolled
Development of a Clinical and Biological Database in Peritoneal Carcinosis (BCB CARCINOSE)
Recruiting·IInstitut du Cancer de Montpellier - Val d'Aurelle·N/A·NCT04221464·600 enrolled
Comparing the Dose-response Profiles of Uterotonics After Initial Carbetocin Administration - an Ex-vivo Study in Desensitized Human Myometrium
Recruiting·SSamuel Lunenfeld Research Institute, Mount Sinai Hospital·N/A·NCT06285409·32 enrolled
Medicare Anti-Aβ mAb Coverage With Evidence Development (CED) Study
Recruiting·CCenters for Medicare and Medicaid Services/ Coverage and Analysis Group·N/A·NCT06058234·8,680 enrolled
Pelacarsen Roll-over Extension Program
Recruiting·Novartis logoNovartis·Phase 3·NCT06875973·599 enrolled
Accelerated ART Initiation for PWHIV Who Are Out of Care
Recruiting·UUniversity of Missouri-Columbia·Phase 4·NCT06374758·120 enrolled
Consistency of Carotid Doppler Blood Flow and Thermodilution Technique
Recruiting·SShanghai Zhongshan Hospital·N/A·NCT05944146·200 enrolled
Page 1 of 22

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)